Signal26 Biotherapeutics is a biotechnology startup dedicated to developing a novel biological treatment for psoriasis. Our project is based on the groundbreaking research by Dr. Gilliet and colleagues at CHUV, which revealed the role of Interleukin-26 (IL-26) in auto-inflammation. By targeting the aberrant activity of IL-26, which contributes to auto-inflammation, we aim to provide relief to millions of patients who currently lack an approved treatment. Our mission is to advance and accelerate the development of this innovative therapy in collaboration with multinational partner organizations while continuing research into other indications in Switzerland.

Signal26 Biotherapeutics is advancing research into signalling pathways involving interleukin 26 and their implications in autoimmune diseases. In parallel, we are developing a monoclonal antibody to IL-26 for the treatment of Pustular Psoriasis.